TRUVADA for PrEP, along with safer sex practices, helped reduce the risk of getting HIV-1 infection in 2 clinical studies.
In the iPrEx Study, TRUVADA for PrEP helped reduce the risk of getting HIV-1 infection in men and transgender women who have sex with men. In the Partners PrEP Study, the medicine helped reduce the risk in male-female couples where one partner was HIV-positive and the other was HIV-negative.
People in both studies were asked to use safer sex practices, including condoms. They also received risk reduction counseling and monthly HIV-1 testing.
Side effects and safety
The most common side effects reported in both studies were stomach-area (abdomen) pain, headache, and decreased weight.
Both studies showed greater protection in people with measureable drug levels.
People in the iPrEx and Partners PrEP studies were asked to take TRUVADA for PrEP every day. Both studies showed a strong link between taking TRUVADA for PrEP every day and how well the medicine works.
Taking medicine exactly as prescribed is called adherence. Ask your doctor any questions you have about how to take TRUVADA for PrEP correctly.
People were asked to use safer sex practices, including condoms. Risk reduction counseling and monthly HIV-1 testing were provided.
TRUVADA for PrEP is part of a complete HIV prevention plan.
You must continue using safer sex practices, including condoms, while you are taking TRUVADA for PrEP. That is because TRUVADA for PrEP is not always effective in preventing HIV-1 infection.